{rfName}
[T

Indexed in

License and use

Icono OpenAccess

Citations

26

Altmetrics

Analysis of institutional authors

Abad Santos, FranciscoAuthorGarcia Garcia, AntonioAuthor

Share

February 10, 2014
Publications
>
Article
Sí

[Treatment of mild cognitive impairment: value of citicoline]

Publicated to:REVISTA DE NEUROLOGIA. 35 (7): 675-682 - 2002-10-01 35(7), DOI: 10.33588/rn.3507.2002390

Authors: Abad-Santos, F; Novalbos-Reina, J; Gallego-Sandín, S; García, AG

Affiliations

- Author
Servicio de Farmacologia Clinica, Instituto Universitario de Gerontologia, Hospital Universitario de la Princesa, Madrid, Espana. fabad@hlpr.insalud.es - Author

Abstract

The course of mild cognitive impairment (MCI) involves a slight loss of memory without any significant effects on other cognitive functions. Around 12% of these patients advance annually toward Alzheimer s disease, and for this reason it is important to search for medications that can prevent or slow down the evolution to dementia. Memory training programs, with relaxation techniques, the repetition of facts, information or pictures, categorizing information and the use of mnemonic rules can be effective. Drugs that can improve the cognitive faculties include piracetam, selegiline, vitamin E, Ginkgo biloba extract, estrogens, nonsteroidal antiinflammatory drugs (NSAIDs), acetylcholinesterase inhibitors and memantine. The aim of this study is to evaluate whether citilcoline can be effective in this clinical situation.It has been shown in several animal models that citicoline improves scoring in learning and memory tests. Likewise, citicoline has been shown to improve memory and other cognitive functions in patients with chronic cerebrovascular disease or dementia and in old people suffering from memory deficit without dementia. Furthermore, a meta analysis of 12 clinical trials conducted by the Cochrane Collaboration, researchers reached the conclusion that citicoline improves memory, behaviour and the overall clinical impression in old people suffering from chronic brain diseases.Citicoline could be effective in the treatment of MCI, although more studies are needed in order to check whether the effect continues in the long term and whether it manages to slow down the progression to dementia.

Keywords

Alzheimers-diseaseAnimalsCdp-cholineCerebrovascular diseasesCiticolineCognitive disordersDementiaDisordersDouble-blindEfficacyEmbryologyHumansL-dopaLevodopaMemoryMild cognitive impairmentNeuronsPerformancePlacebo-controlled trialReviewStimulationUltrastructure

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal REVISTA DE NEUROLOGIA due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2002, it was in position , thus managing to position itself as a Q2 (Segundo Cuartil), in the category Medicine (Miscellaneous). Notably, the journal is positioned en el Cuartil Q4 for the agency WoS (JCR) in the category Clinical Neurology.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 2.63, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-04, the following number of citations:

  • WoS: 9
  • Scopus: 13
  • Europe PMC: 4

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-04:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 68 (PlumX).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.